Envista Holdings's Revenue in the fiscal year 2025 $ 2,718.70 millions
Envista Holdings's Revenue in the fiscal year 2024 $ 2,509.70 millions
Envista Holdings's Revenue in the fiscal year 2023 $ 2,566.50 millions
Envista Holdings's Revenue in the fiscal year 2022 $ 2,569.10 millions
Envista Holdings's Revenue in the fiscal year 2021 $ 2,508.90 millions
NVST Revenue second quarter 2026 Y/Y Growth Comment
Envista Holdings Corporation achieved in the second quarter 2026, above Company average Revenue improvement of 7.13% year on year, to $ 730.50 millions.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 106 other companies have achieved higher Revenue growth. While Envista Holdings Corporation' s Revenue increase of 7.13% ranks overall at the positon no. 2028 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Envista Holdings's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
76.93 %
1.77 %
-33.85 %
(Oct 02 2020)
NVST's II. Quarter Q/Q Revenue Comment
Envista Holdings Corporation achieved in the II. Quarter 2026 above company average sequential Revenue growth of 3.6%, to $ 730.50 millions, from $705.10 millions in the first quarter.
Within Medical Equipment & Supplies industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Envista Holdings's Revenue growth quarter on quarter, overall rank is 1271.
Envista Holdings Corporation achieved in the II. Quarter 2026 above company average sequential Revenue growth of 3.6%, to $ 730.50 millions, from $705.10 millions in the first quarter.
Within Medical Equipment & Supplies industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Envista Holdings's Revenue growth quarter on quarter, overall rank is 1271.
Envista Holdings's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jul 03 2026)
12 Months Ending (Apr 03 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 26 2025)
12 Months Ending (Jun 27 2025)
Cumulative Revenue 12 Months Ending
$ 2,856.40
$ 2,807.80
$ 2,718.70
$ 2,620.60
$ 2,551.70
Y / Y Revenue Growth (TTM)
11.94 %
12.2 %
8.33 %
4.75 %
0.75 %
Year on Year Revenue Growth Overall
Ranking
# 2569
# 1822
# 1811
# 2295
# 1424
Seqeuential Revenue Change (TTM)
1.73 %
3.28 %
3.74 %
2.7 %
1.97 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2431
# 1694
# 1642
# 2170
# 1391
Cumulative Revenue growth Comment
Assuming the Envista Holdings's fiscal year would have ended in Jul 03 2026, Envista Holdings would have reprted above average annual Revenue increase of 11.94% year on year, of $ 2,856 millions. This marks a slow-down of the companys growth trends and from the 12.2% rise in Apr 03 2026.
In the Healthcare sector 369 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1822 to 2569.
Assuming the Envista Holdings's fiscal year would have ended in Jul 03 2026, Envista Holdings would have reprted above average annual Revenue increase of 11.94% year on year, of $ 2,856 millions. This marks a slow-down of the companys growth trends and from the 12.2% rise in Apr 03 2026.
In the Healthcare sector 369 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1822 to 2569.
About Envista Holdings Revenue Growth Rates (NVST), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
10.63%